T1	Participants 62 100	laryngopharyngeal epidermoid carcinoma
T2	Participants 136 267	Twenty-four patients, with a biopsy-proven laryngeal or hypopharyngeal carcinoma, received as an adjunct to their primary treatment
T3	Participants 538 559	healthy control-group
T4	Participants 611 650	patients with laryngo-pharyngeal cancer
